Abstract 19918: Early High-dose Atorvastatin versus Rosuvastatin on Contrast Induced Nephropathy in Acute Coronary Syndromes

Introduction: The PRATO-ACS trial showed that early on-admission high-dose rosuvastatin reduced contrast induced-acute kidney injury (CI-AKI) occurrence and improved clinical outcome in statin-naive patients with non-ST elevation acute coronary syndrome (ACS) scheduled for early invasive strategy. In this noninferiority study we compared the efficacy of high-dose atorvastatin and rosuvastatin in preventing renal damage. Methods: We randomly assigned 700 consecutive statin-naive ACS patients to receive atorvastatin (80 mg on-admission followed by 40 mg/day) or rosuvastatin (40 mg on-admission followed by 20 mg/day). At discharge patients continued the same statin treatment. The primary end-point was CI-AKI (increase in serum creatinine of ≥ 0.5 mg/dl or ≥ 25% above baseline within 72 hours). Persistent renal damage (PRD) (decrease of ≥ 25% in glomerular filtration rate from baseline to 30 days) and adverse clinical events at 12 months were evaluated Results: The study population (67±13 years, 66% men) incl...